Pfizer CentreOne launches Enviero green-chemistry progesterone API

16 Apr 2018

Carbon footprint reduced by more than 70%.

Pfizer CentreOne has introduces Enviero progesterone into the API marketplace. Enviero progesterone is produced by a first-of-its-kind progesterone synthesis developed by Pfizer that reduces waste, greenhouse gas emissions and use of hazardous solvents. Results include cutting the carbon footprint of the progesterone manufacturing process by more than 70% and eliminating the use of metal catalysts. Pfizer CentreOne is a global contract manufacturing organization embedded within Pfizer Inc. and a leading supplier of steroid and hormone APIs and intermediates.

Pfizer CentreOne launches Enviero green-chemistry progesterone API

"Enviero green-chemistry progesterone represents a step change in progesterone API synthesis,” said Greg Scanlon, API business lead for Pfizer CentreOne. “And it’s in keeping with Pfizer’s commitment to reduce its impact on the environment.” Developed over 12 years, Enviero progesterone is manufactured via a proprietary biocatalytic process based on plant sterols. Scanlon continued: “We are pleased to offer Enviero progesterone to customers looking for a reliable supply of high-quality progesterone for their medicines."

Validated process

While new to Pfizer CentreOne customers, Enviero progesterone has been used by Pfizer as an intermediate in the manufacture of its own medications for the past 4 years. More than 500 metric tons have been manufactured to date for internal use.

The compound is manufactured exclusively in the US at Pfizer’s Kalamazoo, Michigan, facility. As with all Pfizer CentreOne APIs, all processing steps for Enviero progesterone are performed under Pfizer’s stringent quality management system, and the compound is backed by technical and regulatory support for the life of the product.

Green chemistry

Enviero progesterone is the first API to be launched from Pfizer CentreOne’s green-chemistry program. According to the US Environmental Protection Agency, “Green chemistry is the design of chemical products and processes that reduce or eliminate the use or generation of hazardous substances.” Green chemistry is applied at the process level – in this case, API synthesis – to minimize waste and pollution upfront.

Read More

Related tags

Market News

Related news

BIA Separations expands with new upstream processing facility

BIA Separations expands with new upstream processing facility

20 Sep 2018

Provides single source of expertise for scaled production of complex biologics for gene therapy and vaccines.

Read more 
Sanofi to refocus two global business units

Sanofi to refocus two global business units

19 Sep 2018

The new Primary Care and China & Emerging Markets global business units are expected to launch at the beginning of 2019.

Read more 
Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years

Experts warn trade and patent changes could increase healthcare cost by $100bn over next 5 years

18 Sep 2018

China is harmonizing to ICH standards at feverish pace and will force poor quality manufacturers out of market.

Read more 
Recipharm connects to European Hub for serialisation compliance

Recipharm connects to European Hub for serialisation compliance

18 Sep 2018

Connection allows the marketing authorisation holders within the Recipharm Group to continue to supply medicines to patients post the EU FMD implementation date.

Read more 
Bosch to unveil new laboratory device for continuous manufacturing

Bosch to unveil new laboratory device for continuous manufacturing

18 Sep 2018

The Xelum R&D offers pharmaceutical manufacturers an ideal start to continuous OSD production.

Read more 
Partnership to deliver integrated, off-the-shelf biosimilar manufacturing solutions

Partnership to deliver integrated, off-the-shelf biosimilar manufacturing solutions

17 Sep 2018

Pall and Aetos to advance the market impact of biosimilars and deliver lower-priced, high-quality options to end users.

Read more 
Cambrex expands manufacturing footprint with acquisition

Cambrex expands manufacturing footprint with acquisition

16 Sep 2018

Completed acquisition adds formulation development and finished dosage manufacturing capabilities to Cambrex’s existing global API manufacturing network.

Read more 
NMPA approves fruquintinib capsules for metastatic colorectal cancer

NMPA approves fruquintinib capsules for metastatic colorectal cancer

13 Sep 2018

Fruquintinib - innovative medicine that has not previously been launched in China or internationally - provides a new therapeutic approach for metastatic colorectal cancer patients.

Read more 
Aptar Pharma to showcase an industry first

Aptar Pharma to showcase an industry first

12 Sep 2018

PureHale is a new portable drug delivery device designed for upper respiratory care.

Read more 
Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio

Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio

11 Sep 2018

The Sandoz US portfolios to be sold to Aurobindo include approximately 300 products, as well as additional development projects.

Read more